Epigenetic modifications and regulators represent potential molecular elements which
control relevant physiological and pathological features, thereby contributing to the natural …

The prostate-specific antigen (PSA) blood test is the accepted biomarker of tumor
recurrence. PSA levels in serum correlate with disease progression, though its diagnostic …

Purpose Diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, causing
overtreatment of indolent PC and risk of delayed treatment of aggressive PC. Here, we …

Prostate cancer (PC) is the most commonly diagnosed neoplasm and the third most
common cause of cancer-related death amongst men in the Western world. PC is a clinically …

The identification of new biomarkers to differentiate between indolent and aggressive
prostate tumors is an important unmet need. We examined the role of THOR (TERT …

Thyroid cancer is a heterogeneous disease with several subtypes characterized by
cytological, histological and genetic alterations, but the involvement of epigenetics is not …

Background. Tumor tissue-associated KLKs (kallikrein-related peptidases) are clinically
important biomarkers that may allow prognosis of the cancer disease and/or prediction of …

Abstract Background Dysregulated expression of Kallikrein-related peptidase 6 (KLK6) is a
common feature for many human malignancies and numerous studies evaluated KLK6 as a …

Purpose Patients with prostate cancer on active surveillance are monitored by repeat
prostate specific antigen measurements, digital rectal examinations and prostate biopsies. A …

Background: Our objective was to evaluate progression-free survival (PFS) and distant
metastasis–free survival (DMFS) as surrogate end points for overall survival (OS) in …